The use of macrolides in treatment of upper respiratory tract infections

Current Allergy and Asthma Reports

Volumn 6, Issue 2, 2006, Pages 171-181

  Wierzbowski, Aleksandra K ^b   Hoban, Daryl J ^b   Hisanaga, Tamiko ^b   DeCorby, Mel ^b   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BACTERIAL PROTEIN; BACTERIAL RNA; BETA LACTAM ANTIBIOTIC; CARBOHYDRATE; CEFACLOR; CISAPRIDE; CLADINOSE; CLARITHROMYCIN; DESOSAMINE; ERM A PROTEIN; ERM B PROTEIN; ERYTHROMYCIN; JOSAMYCIN; LINCOSAMIDE; MACROLIDE; MEF A PROTEIN; MEF E PROTEIN; MIDAZOLAM; MIDECAMYCIN; MIKAMYCIN B; PENICILLIN DERIVATIVE; RIBOSOME PROTEIN; SIMVASTATIN; SPIRAMYCIN; TYLOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HUMAN; MONITORING; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; REVIEW; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 33645778353     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-006-0056-x     Document Type: Review

References (55)

1. Bozdogan B, Appelbaum PC: Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med 2004, 24:455-475.
2. Zhanel GG, Dueck M, Hoban DJ, et al.: Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001, 61:443-498.
3. Zhanel GG, Palatnick L, Nichol KA, et al.: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003, 47:1867-1874.
4. Zhanel GG, Palatnick L, Nichol KA, et al.: Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003, 47:1875-1881.
5. Betriu C, Casado MC, Gomez M, et al.: Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study. Diagn Microbial Infect Dis 1999, 33:255-260.
6. Granizo JJ, Aguilar L, Casal J, et al.: Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000, 46:959-964.
7. Katz KC, McGeer AJ, Duncan CL, et al.: Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003, 47:2370-2372.
8. Reinert RR, Lutticken R, Bryskier A, Al-Lahham A: Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003, 47:489-493.
9. Szczypa K, Sadowy B, Izdebski R, Hryniewicz W: A rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996-2002. J Antimicrob Chemother 2004, 54:828-831.
10. Cascone C, Santagati M, Noviello S, et al.: Macrolide-resistance genes in clinical isolates of Streptococcus pyogenes. Microb Drug Resist 2002, 8:129-132.
11. Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG: Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 2001, 45:2147-2150.
12. Bingen E, Bidet P, Mihaila-Amrouche L, et al.: Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother 2004, 48:3559-3562.
13. Ban N, Nissen P, Hansen J, et al.: The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 2000, 289:905-920.
14. Clancy S, Petitpas J, Dib-Hajj F, et al.: Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mef(A), from Streptococcus pyogenes. Mol Microbiol 1996, 22:867-879.
15. Amezaga MR, Carter PE, Cash P, McKenzie H: Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol 2002, 40:3313-3318.
16. Del Grosso M, Iannelli F, Messina C, et al.: Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol 2002, 40:774-778.
17. Gay K, Stephens DS: Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J Infect Dis 2001, 184:56-65.
18. Pozzi G, Iannelli F, Oggioni MR, et al.: Genetic elements carrying macrolide efflux genes in streptococci. Curr Drug Targets Infect Disord 2004, 4:203-206.
19. Oster P, Zanchi A, Cresti S, et al.: Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother 1999, 43:2510-2512.
20. Seppala H, Skurnik M, Soini H, et al.: A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:257-262.
21. Hasenbein ME, Warner JE, Lambert KG, et al.: Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area. J Clin Microbiol 2004, 42:1559-1563.
22. Kataja J, Huovinen P, Seppala H: Erythromycin resistance genes in group A streptococci of different geographical origins. The Macrolide Resistance Study Group. J Antimicrob Chemother 2000, 46:789-792.
23. Tait-Kamradt A, Davies T, Appelbaum PC, et al.: Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000, 44:3395-3401.
24. Tait-Kamradt A, Davies T, Cronan M, et al.: Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000, 44:2118-2125.
25. Zhanel GG, Hisanaga T, Nichol K, et al.: Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opin Emerg Drugs 2003, 8:297-321.
26. Arpin C, Canron MH, Noury P, Quentin C: Emergence of mef(A) and mef(E) genes in beta-haemolytic streptococci and pneumococci in France. J Antimicrob Chemother 1999, 44:133-134.
27. Montanari MP, Mingoia M, Cochetti I, Varaldo PE: Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol 2003, 41:428-431.
28. Roberts MC, Sutcliffe J, Courvalini P, et al.: Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999, 43:2823-2830.
29. Seppala H, Nissinen A, Yu Q, Huovinen P: Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993, 32:885-891.
30. Bingen E, Leclercq R, Fitoussi F, et al.: Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002, 46:1199-1203.
31. Santagati M, Iannelli F, Oggioni MR, et al.: Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000,44:2585-2587.
32. Adam D, Scholz H: Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group. Eur J Clin Microbiol Infect Dis 1996, 15:712-717.
33. Adelglass J, Jones TM, Ruoff G, et al.: A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998, 18:1255-1263.
34. Amin NM, Breadon G: An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Clin Ther 1995, 17:701-707.
35. Arguedas A, Loaiza C, Rodriguez F, et al.: Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother 1997, 9:44-50.
36. Aronovitz G: A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996, 15:S15-S19.
37. Clement PA, de Gandt JB: A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res 1998, 26:66-75.
38. Cremer J, Wallrauch C, Milatovic D, Braveny I: Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 1998, 17:235-239.
39. Esposito S, De Ritis G, D'Errico G, et al.: Clinical comparison of cefaclor twice daily versus amoxicillin-clavulanate or erythromycin three times daily in the treatment of patients with streptococcal pharyngitis. Clin Ther 1998, 20:72-79.
40. Hashiba M, Baba S: Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996, 525(Suppl):73-78.
41. Kearsley NL, Campbell A, Sanderson AA, et al.: Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. Br J Clin Pract 1997, 51:133-137.
42. Khurana CM: A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996, 15:S24-S29.
43. Marchisio P, Principi N, Sala E, et al.: Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. Antimicrob Agents Chemother 1996, 40:2732-2736.
44. McCarty J: A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. Pediatr Infect Dis J 1996, 15:S10-S14.
45. McCarty JM: Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis. Eur J Clin Microbiol Infect Dis 1994, 13:846-850.
46. McLinn S: A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996, 15:S20-S23.
47. Pacifico L, Scopetti F, Ranucci A, et al.: Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996, 40:1005-1008.
48. Principi N: Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995, 14:669-676.
49. Rodriguez AF: An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother 1996, 37(Suppl C):63-69.
50. Schaad UB, Heynen G: Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. Pediatr Infect Dis J 1996, 15:791-795.
51. Scholz H, Noack R: Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group. Eur J Clin Microbiol Infect Dis 1998, 17:470-478.
52. Venuta A, Laudizi L, Beverelli A, et al.: Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res 1998, 26:152-158.
53. Pavlopoulou J, Leotsacos P, Sereti E, et al.: Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children. J Chemother 1995, 7(Suppl 4):150-153.
54. O'Doherty B: Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1996, 15:718-724.
55. Rzeszutek M, Wierzbowski A, Hoban DJ, et al.: A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 2004, 24:95-104.